India's Mankind Pharma rises on buying new drug rights

Mankind Pharma

18/03/2026 06:01

** Shares of India's Mankind Pharma MNKI.NS rise nearly 3% to 2122 rupees, snapping four day losing streak

** Co buys Rivotril brand from Roche ROG.S for India

** Co acquires exclusive rights to manufacture, market and distribute Rivotril in India

** Rivotril is widely prescribed for the management of neurological and psychiatric conditions.

** MNKI rated "buy" on avg by 17 analysts covering it; median PT at 2500 rupees- data compiled by LSEG

** YTD, MNKI down 3.4%

 (Reporting by Komal Salecha in Bengaluru)

 ((Komal@thomsonreuters.com))